The Use of Faster Acting Aspart in Type 1 Diabetes Patients

Antwerp University Hospital (UZA)

Status: Completed

Conditions: Type 1 Diabetes; Insulin; Time in Range

Study type: Observational

Funder types: Other

Identifiers

NCT04711382

Fiasp real-world data

Details and patient eligibility

About

Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a "real-world" clinical practice setting in people with type 1 diabetes in Belgium.

Full description

The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T<70 and T<54 mg/dl) and time above range (T>180 and T>250 mg/dl).

Retrospective analysis Two-center study

Enrollment: 438 patients

Sex: All

Ages: 16 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 1 diabetes patients
• Duration of diabetes > 2 years
• Using CGM for > 6 months

Exclusion criteria

• Using SMBG
• Pregnancy
• Using glucocorticoids or immunosuppressive agents
• Active oncological problem